What's new ? - 2018

What's new ? - 2018

Boehringer Ingelheim to invest €65 million in avian vaccines

17 April, 2018

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Porte-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines.
The German group has laid the first stone of a 5,700 sq m building at its Lyon Porte-des-Alpes (LPA) site. Known as F2IVE (Formulation and Filling of Inactivated Vaccines Extension), this major project will comprise a three-storey building - including 1,000 sq m of clean room space – mainly for formulating and distributing avian vaccines.
As poultry consumption continues to rise around the world, there is an increasing demand for avian vaccines. This meant that our LPA production site in Saint-Priest was going to reach a saturation point by 2020.
The new building, which has an environmentally friendly design, will house two formulation lines, a multi-format bottle distribution line and a bag distribution area.